Graft rejection is a common problem after alternative donor transplantation for patients with refractory severe aplastic anemia (SAA). Intensification of the conditioning regimen, with the inclusion of irradiation, has often been advocated to combat this problem. With this approach engraftment rate improved, but the incidence of transplant-related complications is also increased, resulting in little change in the overall outcome. We investigated the use of the combination of fludarabine, cyclophosphamide and anti-thymocyte globulin as the conditioning regimen in five multiply-transfused SAA patients. Three patients received an HLA one-antigen disparate related donor transplant, while two patients were given marrow from matched, unrelated donors. The regimen was well tolerated, with only grade I toxicity encountered. With a median follow-up of 9 months, all patients are alive with complete donor chimerism. We conclude that fludarabine may be used in place of irradiation to augment the conditioning regimen of cyclophosphamide and anti-thymocyte globulin for alternative donor transplantation in children with SAA. Bone Marrow Transplantation (2001) 27, 125-128.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for children with severe aplastic anemia (SAA). Unfortunately the majority of patients lack an HLA-identical sibling donor. Transplantation using a mismatched related or unrelated donor is associated with a high incidence of rejection in this population of previously heavily transfused patients. [1] [2] [3] [4] To overcome this obstacle, an increase in intensity of immunosuppression in alternative donor transplants was thought to be necessary. A number of authors reported the inclusion of irradiation in the conditioning regimen. [5] [6] [7] While the rate of engraftment appeared to have increased, improvement in transplant outcome has been less impressive. [1] [2] [3] [4] 8, 9 In addition, the shortand long-term side-effects of irradiation are of concern, especially in the pediatric age group. Recently, fludarabine was reported to facilitate allogeneic marrow engraftment with tolerable side-effects. Most of the data, however, involved patients with underlying malignancies. 10, 11 We applied a fludarabine-based, chemotherapy-only regimen in five refractory SAA patients receiving HSCT from alternative donors and report our results here.
Patients and methods

Patients
From September 1999 to February 2000, five children with SAA received fludarabine, CY and ATG as conditioning before allogeneic HSCT. All patients had previously failed immunosuppressive therapy and did not have an HLAmatched sibling donor. Median interval from diagnosis to HSCT was 36 months (range 8 to 57 months) and all were transfusion-dependent at the time of transplant. In all patients, Fanconi anemia was excluded by diepoxybutane testing of peripheral blood lymphocytes for increased chromosome breakage. Patient 4 was suspected to have Diamond-Shwachmann syndrome based on short stature and fibrosis of the pancreas seen on MRI scan. Other patient characteristics are listed in Table 1 . All patients had normal organ functions, absence of active infections or concomitant life-threatening illness. The selection of donors was based on HLA serologic typing performed for class I and II antigens and molecular typing by sequence specific oligonucleotide probes for the DRB1 loci.
Preparative regimen
Informed consent was obtained from the parents. 
GVHD prophylaxis and treatment
Patients 1 to 3 received CsA 3 mg/kg/day i.v. by continuous infusion from day −1. They also received methylprednisolone 0.5 mg/kg/day i.v. from day 7 to 14, 1.0 mg/kg/day from day 15 to 28, and 0.5 mg/kg/day day 29 to 42, followed by tapering over 2 to 3 weeks. Patients 4 and 5 received tacrolimus 0.03 mg/kg/day i.v. by continuous infusion from day −2. They also received MTX 5 mg/m 2 i.v. on days 1, 3, 6, and 11. Following engraftment, when the patient was able to eat, CsA or tacrolimus was converted to oral administration to day 180 and tapered thereafter.
Supportive care
All blood products were irradiated and filtered. Red blood cell and platelet transfusions were given to maintain a hemoglobin of Ͼ80 g/l and platelet count Ͼ20 × 10 9 /l. Patients 4 and 5 received filgrastim 5 g/kg/day s.c. from day 1 after marrow infusion. It was continued until the neutrophil count exceeded 1.5 × 10 9 /l for 3 days. Infection prophylaxis during the peritransplant period consisted of acyclovir 5 mg/kg i.v. every 8 h. All patients received broad-spectrum antibiotics for neutropenic fever and hyperalimentation when needed. Intravenous immunoglobulin prophylaxis was given until day 100. When engraftment occurred the patient received twice-weekly trimethoprim-sulfamethoxazole or weekly dapsone orally, and CMV-seropositive patients received prophylactic ganciclovir to day 100.
Assessment of engraftment and response
Myeloid engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count Ͼ0.5 × 10 9 /l, and platelet recovery was defined as the day the platelet count was Ͼ20 × 10 9 /l with no platelet transfusions the following week. Bone marrow aspirates were examined for morphology and cellularity at 1, 3 and 6 months after transplant. Hematopoietic chimerism was evaluated by conventional cytogenetics and FISH for sex-mismatched patientdonor pairs, and by DNA restriction fragment length polymorphism for sex-matched pairs. Regimen-related toxicity was graded according to the Bearman criteria.
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Results
Engraftment and outcome
A median of 6.12 × 10 8 nucleated cells/kg body weight was infused. All patients showed complete hematological reconstitution of donor origin. Median time to ANC Ͼ0.5 × 10 9 /l was 14 days (range 0-18); the median time to attain a platelet count of Ͼ20 × 10 9 /l was 17 days (range 14-52). All patients have become transfusion-independent. Repeated chimerism analysis of peripheral blood and bone marrow revealed 100% donor hematopoiesis in all patients. On 1 July 2000 all patients are alive 150 to 303 days (median 255 days) after transplant.
Toxicity
The preparative regimen was well tolerated. There was minimal oral mucositis or enteritis (grade I). No patient required intravenous narcotics for pain control. Patient 5 maintained an ANC Ͼ0.5 × 10 9 /l throughout, and did not require hyperalimentation during hospitalization. No renal or hepatic toxicity was detected. All patients developed fever that responded to appropriate antibiotic therapy. Patient 4 developed decreased consciousness level, irregular respiration and seizures the day after marrow infusion. The clinical picture was compatible with tacrolimus neurotoxicity and this was confirmed by an elevated blood tacrolimus level and abnormalities of the occipital region on a MRI of the brain. Her symptoms resolved quickly after transient withholding of the medication. This patient developed idiopathic diffuse alveolar hemorrhage on day +25 during the phase of acute GVHD, but recovered after ventilatory support.
GVHD
Acute GVHD was diagnosed in all but patient 5. Patients 1 and 2 had grade II, steroid-responsive disease. Chronic GVHD, limited to the skin, developed subsequently. Patients 3 and 4 had grade III visceral and skin GVHD that required ATG, IL2-R antagonist and TNF antibody therapy. Both have ongoing extensive chronic GVHD requiring continual immunosuppressive treatment.
Discussion
The prognosis for patients with refractory SAA is poor. While allogeneic HSCT using alternative donors can be curative, the results have been improving, but slowly. For example, the EBMT registry reported a 5-year survival of 84 HLA mismatched family donor transplants of only 15%. 2 A recent report from the National Marrow Donor Program on 141 patients showed a median 36-month survival of 36%. 3 The poor outcome of these transplants is multifactorial. Patients are often multiply-transfused, with resultant allosensitization to minor histocompatibility antigens. Profound neutropenia of long duration also leads to repeated infections and poor general condition. A higher incidence of severe acute GVHD was seen. 3, 4 Morbidity and mortality of BMT were high. 1, 4 The incidence of graft failure in this population ranged from 10 to 71%. 13 Intensification of the preparative regimen by the addition of irradiation, either as limited field or total body irradiation to CY, has been advocated to minimize graft rejection.
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The outcome of irradiation-based, alternative donor BMT has been variable. 4, 8, 9 Recent reports of unrelated donor BMT have been somewhat better. Using T cell depletion and an intensive, TBI-based conditioning regimen, Margolis et al 14 showed an overall survival of 54%. Similarly, a preliminary report showed eight of 12 patients were alive with a conditioning regimen of 200 cGy of TBI and CY. 15 Patients who had received irradiation had a higher incidence of GVHD and interstitial pneumonitis. 8, 9 The incidence of second malignancies has been high, up to 22% at 8 years, even in patients who received a limited field of irradiation. 16 In addition, the long-term effects of irradiation on physical growth, fertility and hormone production are of concern. Avoidance of radiation in the preparative regimen is clearly desirable.
The experience of chemotherapy-only conditioning regimens in alternative donor transplants for SAA is limited. Deeg et al 17 reported poor graft function in three of four unrelated donor BMT recipients after conditioning with cyclophosphamide plus ATG. On the contrary, Abella et al 18 observed engraftment in 13 of 14 patients, but the total dose of ATG used in the combination was much higher.
Purine-analogs, in particular fludarabine, possess powerful immunosuppressive activities with mild systemic toxicity. Fludarabine-based preparative regimens were sufficient to engraft patients with hematologic malignancies, using either matched sibling or alternative donors. 10, 11 Therefore fludarabine would be an attractive agent to be incorporated into a conditioning regimen for HSCT of SAA patients. However the ability of these patients to reject a transplant remains a concern. First, their immune system may be more intact than that of leukemia or lymphoma patients who have had prior anti-cancer therapy. Furthermore, frequent transfusion of blood products in SAA patients could have enhanced the allogeneic resistance to Bone Marrow Transplantation alternative donor grafts. The number of prior transfusions and the interval between diagnosis and transplantation have both been shown to adversely affect post-transplant survival. 3, 4, 8 All our patients were heavily transfused prior to HSCT. It is therefore reassuring that all our patients engrafted despite the unfavorable prognostic factors.
Considering the general condition of our patients and the chronicity of their marrow aplasia, the combination of fludarabine, cyclophosphamide and ATG was well tolerated. No significant bowel, renal or liver toxicity was encountered. This experience is in keeping with reports of mild morbidity in unfit lymphoma patients transplanted after fludarabine and cyclophosphamide. 19 Preliminary results of alternative donor HSCT in two aplastic anemia patients reported by Bacigalupo et al 20 also confirmed the lack of significant regimen-related toxicity of this combination.
The results from this series must be considered preliminary due to the small number of patients treated. The duration of follow-up is still fairly short, although all but the last patient have sustained donor engraftment for over 6 months and are off GVHD prophylaxis. A lower graft rejection rate in recent years in HLA-identical sibling transplants was attributed to the more potent GVHD prophylaxis (with CsA or tacrolimus and MTX) employed. 4, 8 It may have contributed to the higher engraftment rate in our patients. However, such an effect has not been documented in mismatched related donor transplant recipients. 21 In summary, this fludarabine-based conditioning regimen was sufficiently immunosuppressive to allow engraftment with unmanipulated HSC grafts from alternative donors, and did not cause significant regimen-related toxicity. However, the risk of GVHD remained significant, and the ultimate success of this regimen depends on findings ways of decreasing the incidence of this complication.
